Zhang Y - Search Results

1

EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.

Qin Z, Yue M, Tang S, Wu F, Sun H, Li Y, Zhang Y, Izumi H, Huang H, Wang W, Xue Y, Tong X, Mori S, Taki T, Goto K, Jin Y, Li F, Li FM, Gao Y, Fang Z, Fang Y, Hu L, Yan X, Xu G, Chen H, Kobayashi SS, Ventura A, Wong KK, Zhu X, Chen L, Ren S, Chen LN, Ji H. Qin Z, et al. Among authors: zhang y. J Exp Med. 2024 Mar 4;221(3):e20232028. doi: 10.1084/jem.20232028. Epub 2024 Jan 29. J Exp Med. 2024. PMID: 38284990

2

EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.

Jiang T, Zhang Y, Li X, Zhao C, Chen X, Su C, Ren S, Yang N, Zhou C. Jiang T, et al. Among authors: zhang y. Eur J Cancer. 2019 Nov;121:98-108. doi: 10.1016/j.ejca.2019.08.021. Epub 2019 Sep 27. Eur J Cancer. 2019. PMID: 31569068

3

Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study.

Wei W, Zhou J, Zhang Q, Liao DH, Liu QD, Zhong BL, Liang ZB, Zhang YC, Jiang R, Liu GY, Xu CY, Li Zhou H, Zhu SY, Yang N, Jiang W, Liu ZG. Wei W, et al. Cancer Med. 2020 Apr;9(8):2820-2832. doi: 10.1002/cam4.2937. Epub 2020 Feb 26. Cancer Med. 2020. PMID: 32100444 Free PMC article. Clinical Trial.

4

Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.

Zhang Y, Zeng L, Zhou C, Li Y, Wu L, Xia C, Jiang W, Hu Y, Liao D, Xiao L, Liu L, Yang H, Xiong Y, Guan R, Lizaso A, Mansfield AS, Yang N. Zhang Y, et al. J Thorac Oncol. 2020 Jun;15(6):1027-1036. doi: 10.1016/j.jtho.2020.02.007. Epub 2020 Feb 27. J Thorac Oncol. 2020. PMID: 32112982 Free article.

5

A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.

Zhou Y, Jiang W, Zeng L, Mi J, Song L, Lizaso A, Mao X, Yang N, Zhang Y. Zhou Y, et al. Among authors: zhang y. Lung Cancer. 2020 May;143:55-59. doi: 10.1016/j.lungcan.2020.03.019. Epub 2020 Mar 19. Lung Cancer. 2020. PMID: 32208297

6

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.

Zhang Y, Zhang X, Zhang R, Xu Q, Yang H, Lizaso A, Xu C, Liu J, Wang W, Ou SI, Zhang J, Song Z, Yang N. Zhang Y, et al. Among authors: zhang r, zhang j, zhang x. BMC Med. 2021 Sep 13;19(1):206. doi: 10.1186/s12916-021-02082-6. BMC Med. 2021. PMID: 34511132 Free PMC article.

7

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.

Zhang Y, Zeng L, Zhang X, Li Y, Liu L, Xu Q, Yang H, Jiang W, Lizaso A, Qiu L, Hou T, Liu J, Peng L, Yang N. Zhang Y, et al. Among authors: zhang x. BMC Med. 2021 Oct 19;19(1):245. doi: 10.1186/s12916-021-02118-x. BMC Med. 2021. PMID: 34663309 Free PMC article.

8

Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.

Zhou Y, Song L, Xu Q, Zeng L, Jiang W, Yang N, Zhang Y. Zhou Y, et al. Among authors: zhang y. Lung Cancer. 2022 May;167:58-64. doi: 10.1016/j.lungcan.2022.04.002. Epub 2022 Apr 6. Lung Cancer. 2022. PMID: 35405360

9

The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer.

Zhao C, Li J, Zhang Y, Han R, Wang Y, Li L, Zhang Y, Zhu M, Zheng J, Du H, Hu C, Zhou C, Yang N, Cai S, He Y. Zhao C, et al. Among authors: zhang y. Cancer Med. 2023 Mar;12(5):5603-5614. doi: 10.1002/cam4.5410. Epub 2022 Nov 7. Cancer Med. 2023. PMID: 36341686 Free PMC article.

10

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer.

Li H, Zhang Y, Xu Y, Huang Z, Cheng G, Xie M, Zhou Z, Yu Y, Xi W, Fan Y. Li H, et al. Among authors: zhang y. Cell Death Dis. 2022 Dec 21;13(12):1064. doi: 10.1038/s41419-022-05510-4. Cell Death Dis. 2022. PMID: 36543792 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239,213 results

Search Page